戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 th the required four times a day dosing with ipratropium.
2 performed placebo, but not glycopyrrolate or ipratropium.
3 corticosteroids, 1.11 (CI, 1.08 to 1.15) for ipratropium, 0.92 (CI, 0.88 to 0.96) for long-acting bet
4 zation rates were similar in the two groups (ipratropium: 8 of 79 children [10.1 percent]; control: 9
5                               Tiotropium and ipratropium, a structurally similar muscarinic antagonis
6 of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and plac
7             The possible association between ipratropium and elevated risk for all-cause and cardiova
8               The subjects were treated with ipratropium bromide (84 microgram) or normal saline solu
9             Inhaled anticholinergics such as ipratropium bromide (IB), when administered with beta2-a
10 ization of a mixture of albuterol 2.5 mg and ipratropium bromide 0.5 mg.
11 ved either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or place
12 mpare the effects between pretreatments with ipratropium bromide and placebo aerosols on the airway r
13                           Our data show that ipratropium bromide increases the ability of the nose to
14                                              Ipratropium bromide led to less reduction in the cold, d
15                                    Either 1) ipratropium bromide nasal spray 0.06% in buffered salt s
16 sed it to study the effect of treatment with ipratropium bromide on the ability of the nose to condit
17  of a metered-dose inhaler containing either ipratropium bromide or placebo (two inhalations three ti
18                    Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely us
19                                   Intranasal ipratropium bromide provides specific relief of rhinorrh
20                 Thus, treating rhinitis with ipratropium bromide should not increase the burden for i
21 vere exacerbation of asthma, the addition of ipratropium bromide to albuterol and corticosteroid ther
22                                              Ipratropium bromide treatment significantly increased na
23                                              Ipratropium bromide was provided as rapid-relief treatme
24 as-needed albuterol use was discontinued and ipratropium bromide was used as needed.
25 c corticosteroids and inhaled albuterol with ipratropium bromide were randomly assigned to 3 nebulize
26 ed (1:1) to receive nebulised salbutamol and ipratropium bromide with either 2.5 mL of isotonic MgSO(
27 atment group received 500 microg (2.5 ml) of ipratropium bromide with the second and third doses of a
28 butamol) and a short-acting anticholinergic (ipratropium bromide), in COPD is encouraging because the
29 ing responsiveness to inhaled salbutamol and ipratropium bromide.
30 rovided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a mo
31          More importantly, pretreatment with ipratropium completely prevented the HA-induced bronchoc
32 amol was equal to or greater than that after ipratropium for all phenotypes.
33 the rate of hospitalization was lower in the ipratropium group (59 of 215 children [27.4 percent]) th
34 er rates of blood-tinged mucus (16.8% in the ipratropium group compared with 3.6% in the control grou
35 p; P = 0.01) and nasal dryness (11.7% in the ipratropium group compared with 3.6% in the control grou
36          Anticholinergic medications such as ipratropium improve the pulmonary function of patients w
37 e of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructi
38 o COPD medications, inhaled corticosteroids, ipratropium, long-acting beta-agonists, and theophylline
39  (n = 3), or short-acting beta2-agonist plus ipratropium (n = 3).
40            Neither the muscarinic antagonist ipratropium nor the phospholipase C inhibitor U73122, no
41 orrhea as judged subjectively was reduced in ipratropium recipients by 31% compared with controls and
42                                              Ipratropium recipients had 26% less nasal discharge than
43 n asthma score of 12 to 15), the addition of ipratropium significantly reduced the need for hospitali
44 iveness of treatment were more favorable for ipratropium than for the control spray (P < or = 0.026)
45                                    Following ipratropium, the corresponding change was -1.32 +/- 0.85
46 l corticosteroid and 3 inhaled albuterol and ipratropium treatments.
47                                              Ipratropium was associated with increased cardiovascular
48 the severity of rhinorrhea (P < or = 0.003), ipratropium was associated with reduced sneezing on stud
49                                              Ipratropium was generally well tolerated but was associa
50  In head-to-head comparisons, astemizole and ipratropium were outperformed by several interventions.